Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07584876
PHASE1

A Phase 1 Clinical Study in Healthy Participants

Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-05-15

Completion Date

2028-01-31

Last Updated

2026-05-13

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

Locations (1)

Argo Investigative Site

Perth, Western Australia, Australia